Discover Top Posts Tagged with #asp-2215

Gilteritinib for Treatment of Acute Myeloid Leukemia

Gilteritinib ASP-2215 Treatment of Acute Myeloid Leukemia 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide C29H44N8O3, 552.71 Phase III A FLT3/AXL inhibitor potentially for the treatment of acute myeloid leukemia. CAS No. 1254053-43-4 Astellas Pharma INNOVATOR Mechanism Of Action Axl receptor tyrosine kinase inhibitors, Fms-like…

View On WordPress

#1254053-43-4 #Acute Myeloid Leukemia #ASP-2215 #ASTELLAS PHARMA #Gilteritinib #PHASE 3

Gilteritinib for Treatment of Acute Myeloid Leukemia

Gilteritinib

ASP-2215

Treatment of Acute Myeloid Leukemia

6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide

C29H44N8O3, 552.71

Phase III

A FLT3/AXL inhibitor potentially for the treatment of acute myeloid leukemia.

CAS No. 1254053-43-4

Astellas Pharma INNOVATOR Mechanism Of Action Axl receptor tyrosine kinase inhibitors,…

View On WordPress

#1254053-43-4 #Acute Myeloid Leukemia #ASP-2215 #Astellas Pharma #Gilteritinib #phase 3

#asp-2215

Trending Tags

Recently Viewed Tags

#asp-2215